|Systematic (IUPAC) name|
|Molar mass||451.777 g/mol|
Rosonabant (INN; E-6776) is a drug acting as a CB1 receptor antagonist/inverse agonist that was under investigation by Esteve as an appetite suppressant for the treatment of obesity. Development of the drug for clinical use was apparently halted shortly after the related CB1 antagonist rimonabant was discontinued, likely due to the reports of severe psychiatric adverse effects such as anxiety, depression, and suicidal ideation associated with it and with similarly-acting agents.
- Janero DR, Makriyannis A (March 2009). "Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis". Expert Opinion on Emerging Drugs. 14 (1): 43–65. doi:10.1517/14728210902736568. PMID 19249987.
- Tim C. Kirkham; S. J. Cooper (2007). Appetite and Body Weight: Integrative Systems and the Development of Anti-Obesity Drugs. Academic Press. p. 325. ISBN 978-0-12-370633-1. Retrieved 12 May 2012.
- Heal DJ, Gosden J, Smith SL (December 2009). "Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders". British Journal of Clinical Pharmacology. 68 (6): 861–74. doi:10.1111/j.1365-2125.2009.03549.x. PMC . PMID 20002080.
- Lee HK, Choi EB, Pak CS (2009). "The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents". Current Topics in Medicinal Chemistry. 9 (6): 482–503. doi:10.2174/156802609788897844. PMID 19689362.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|